PureTech is a clinical-stage biotherapeutics company developing highly differentiated medicines for devastating diseases. Its platform has produced a broad pipeline across wholly owned programs and founded entities, with a focus on brain-immune-gut biology and other areas of high unmet need.
PureTech Health's deupirfenidone has received Orphan Drug Designation from both the U.S. FDA and European Commission for treating idiopathic pulmonary fibrosis, a rare and fatal lung disease. Phase 2b trial results showed superior efficacy compared to existing therapies.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07456800 |
PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects |
COMPLETED | PHASE1 |
| NCT07284602 |
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) |
NOT_YET_RECRUITING | PHASE3 |
| NCT06717100 |
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib |
COMPLETED | PHASE1 |
| NCT05829226 |
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) |
COMPLETED | PHASE1 |
| NCT05321420 |
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05129865 |
LYT-300 in Healthy Volunteers |
COMPLETED | PHASE1/PHASE2 |
| NCT04666688 |
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors |
COMPLETED | PHASE1/PHASE2 |
| NCT04652518 |
LYT-100 in Post-acute COVID-19 Respiratory Disease |
TERMINATED | PHASE2 |
| NCT04243837 |
LYT-100 in Patients With BCRL |
TERMINATED | PHASE2 |
